The Use of IO Doublet in PD-L1-Negative NSCLC

David Carbone

Metastatic EGFRm NSCLC: 1L Therapy Options

University of Colorado Cancer Center

T. Patil

ESMO 2024 Summary: Management of Oligoprogressive Disease - Patients…

2024 ESMO Annual Meeting Insights Hub

R. Van den Begin

Year in Review 2024 - Transformative FDA Approvals in Precision Onco…

Oncology 2024 Year in Review

V. Subbiah

Multidisciplinary Panel Discussion: New Treatment Options for Surgic…

David Carbone

B. Stiles

2024 Intervention Selection & Sequencing in Early Stage NSCLC

Total Health

J. Porter

ASCO® 2024 Lung Cancer Highlights: Top Abstracts Including BEAT-SC, …

2024 ASCO® Annual Meeting Insights Hub

B. Halmos

Mediastinal Staging of Lung Cancer

MI&T Congressi

R. Trisolini

WCLC 2024 Insights: Interstitial Lung Disease and Lung Cancer - How …

Insights from 2024 WCLC

S. Ikeda

ESMO 2024 Summary: EGFRm NSCLC Panel Discussion - MARIPOSA, PAPILLON…

ecancer

I. Gil-Bazo, M. Brandão, B. Besse, E. Felip

Year in Review: Lung Cancer

Balazs Halmos

Treatment Updates in Advanced and Metastatic NSCLC - Advances in Tho…

Total Health

J. Porter

Hyperprogression in Cancer Treated With Immunotherapy

Northwestern Medicine Oncology and Hematology

Y. Chae

UChicago Medicine Best of ASCO® 2024: NSCLC

UChicago Medicine Annual Practice Updates in Hematology and Oncology

R. Thawani

ASCO® 2024 Lung Cancer Roundtable: Advances in NSCLC

ecancer

E. Felip, A. Spira, A. Passaro, A. Addeo

World Lung Cancer Day: Key Insights and Advances in Lung Cancer Trea…

Oncology Data Advisor

S. Kareff, B. Sandy, M. Vojnic

Controversies in NSCLC: Neoadjuvant vs. Adjuvant IO in Early Stage D…

Luis Raez

Checkpoint Inhibitors, Arthritis and Other Autoimmune Triggers

West Virginia State Rheumatology Society

J. Bustamante

Management of mNSCLC Without Actionable Mutations

Integrity CE

M. Baumgart, S. Liu

ASCO® 2024 Insights: "KRYSTAL-12 Study - Adagrasib vs. Docetaxel in …

2024 ASCO® Annual Meeting Insights Hub

T. Mok